
    
      This study was conducted in 893 facilities in Korea from 2 Apr 2012 to 1 Apr 2017. This study
      was designed to administer 1mg, 2mg, or 4mg pitavastatin to patients with hyperlipidemia at
      the age of 20 or older for at least 8 weeks.
    
  